Perspective · 19 Mar 2025
Conference abstractPublished 17 Jul 2017
Is elevated troponin T reliable enough to be the only screen-out factor in pre-treated lymphoma patients?
PSI Company Ltd, Russia; PSI Pharma Support America Inc, USA; PSI CRO Deutschland GmbH, Germany
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Summarizing our experience of medical monitoring in clinical studies in patients with relapsed diffuse large B-cell lymphoma (DLBCL) pre-treated with standard Rituximab based scheme, we were surprised by a rather high incidence of increased Troponin T (TnT) in patients that had no detectable cardiac pathology. Such patients were screened out even if this lab finding was the only contraindication for inclusion. Purpose: To accumulate literature data confirming that in this particular group of patients mildly elevated TnT measured by immunoassay and not supported by any overt cardiovascular manifestations can be caused by reasons other than cardiovascular pathology. Therefore such patient can be included in the study and have potential benefit from treatment. Findings: About 10-11% of patient’s serum samples may contain HAMA (human anti-mouse antibodies), which lead to false positive results of troponin immunoassay. Oncology patients, especially treated with monoclonal antibodies (Mab)-based immunotherapy are at significantly higher risk of HAMA development. Available literature data suggest that quantitative measurement of HAMA in oncology patients has far more practical impact than simple confirmation of ambiguous immunoassay results. Survival benefit associated with HAMA in patients with B-cell malignancies and with non-Hodgkin’s lymphoma treated with anti-lymphoma Mab had been demonstrated. Conclusion: HAMA measurement in potentially eligible patients who had previously received Mab immunotherapy and whose only contraindication for inclusion into the clinical study is mildly elevated TnT, seems justified. First, the patients with the false-positive TnT results caused by HAMA, will be included and may have potential benefits from study treatment. Second, the result of the HAMA test may have predictive value for treatment benefit.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Immunotherapy: Open Access.
Perspective · 19 Mar 2025
Advancing Immunotherapy: Future Directions in the Fight against Renal Cell Carcinoma
Short communication · 19 Mar 2025
Emerging Therapies: The Latest Developments in Autoimmune Disease Management
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalImmunotherapy: Open Access
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Nickolai Usachev”
- BylineArticles whose byline prints “Maxim Kosov”
- BylineArticles whose byline prints “John Riefler”
- BylineArticles whose byline prints “Maxim Belotserkovskiy”
- BylineArticles whose byline prints “Anna Kuzina”
